Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphologyHUMPHREY, R. W; OHAGEN, A; DAVIS, D. A et al.Antimicrobial agents and chemotherapy. 1997, Vol 41, Num 5, pp 1017-1023, issn 0066-4804Article

Current knowledge and future prospects for the use of HIV protease inhibitorsMOYLE, G; GAZZARD, B.Drugs (Basel). 1996, Vol 51, Num 5, pp 701-712, issn 0012-6667Article

In vitro anti-HIV activity of HIV protease inhibitor KNI-272 in resting and activated cells : implications for its combined use with AZT or ddISUDHICHAI CHOKEKIJCHAI; SHIRASAKA, T; WEINSTEIN, J. N et al.Antiviral research. 1995, Vol 28, Num 1, pp 25-38, issn 0166-3542Article

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteinsKAGEYAMA, S; ANDERSON, B. D; HOESTEREY, B. L et al.Antimicrobial agents and chemotherapy. 1994, Vol 38, Num 5, pp 1107-1111, issn 0066-4804Article

Targets of a protease inhibitor, KNI-272, in HIV-1-infected cellsGOTO, Toshiyuki; NAKANO, Takashi; KOHNO, Takehiro et al.Journal of medical virology. 2001, Vol 63, Num 3, pp 203-209, issn 0146-6615Article

Solution structure of HIV-1 protease-allophenylnorstatine derivative inhibitor complex obtained from molecular dynamics simulationKATO, R; TAKAHASHI, O; KISO, Y et al.Chemical and pharmaceutical bulletin. 1994, Vol 42, Num 1, pp 176-178, issn 0009-2363Article

Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats : effect of solventSUGAHARA, M; KIRIYAMA, A; HAMADA, Y et al.Biopharmaceutics & drug disposition. 1995, Vol 16, Num 4, pp 269-277, issn 0142-2782Article

Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitorKIRIYAMA, A; NISHIURA, T; YAMAJI, H et al.Biopharmaceutics & drug disposition. 1999, Vol 20, Num 4, pp 199-205, issn 0142-2782Article

In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatineKAGEYAMA, S; MIMOTO, T; BRODER, S et al.Antimicrobial agents and chemotherapy. 1993, Vol 37, Num 4, pp 810-817, issn 0066-4804Article

Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosingMUELLER, B. U; ANDERSON, B. D; BALIS, F. M et al.Antimicrobial agents and chemotherapy. 1998, Vol 42, Num 7, pp 1815-1818, issn 0066-4804Article

A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infectionHUMPHREY, R. W; WYVILL, K. M; MITSUYA, H et al.Antiviral research. 1999, Vol 41, Num 1, pp 21-33, issn 0166-3542Article

HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombinationYUSA, K; KAVLICK, M. F; KOSALARAKSA, P et al.Antiviral research. 1997, Vol 36, Num 3, pp 179-189, issn 0166-3542Article

The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogsKIRIYAMA, A; SUGAHARA, M; YOSHIKAWA, Y et al.Biopharmaceutics & drug disposition. 1996, Vol 17, Num 2, pp 125-134, issn 0142-2782Article

Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitorKIRIYAMA, A; NISHIURA, T; ISHINO, M et al.Biopharmaceutics & drug disposition. 1996, Vol 17, Num 9, pp 739-751, issn 0142-2782Article

Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomesKIRIYAMA, A; NISHIURA, T; YAMAJI, H et al.Antimicrobial agents and chemotherapy. 1999, Vol 43, Num 3, pp 549-556, issn 0066-4804Article

Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmaceutic characteristics in rats after intravenous and intraduodenal administrationsKIRIYAMA, A; MIMOTO, T; KISANUKI, S et al.Biopharmaceutics & drug disposition. 1993, Vol 14, Num 8, pp 697-707, issn 0142-2782Article

Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administrationKIRIYAMA, A; FUJITA, K; TAKEMURA, S et al.Biopharmaceutics & drug disposition. 1994, Vol 15, Num 7, pp 617-626, issn 0142-2782Article

New water-soluble prodrugs of HIV protease inhibitors based on O→N intramolecular acyl migrationHAMADA, Yoshio; OHTAKE, Jun; SOHMA, Youhei et al.Bioorganic & medicinal chemistry. 2002, Vol 10, Num 12, pp 4155-4167, issn 0968-0896, 13 p.Article

Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostereMIMOTO, Tsutomu; HATTORI, Naoko; IMAI, Junya et al.Chemical and pharmaceutical bulletin. 2000, Vol 48, Num 9, pp 1310-1326, issn 0009-2363Article

A phase I/II study of the safety and activity of a microsphere formulation of KNI-272 in patients with HIV-1 infectionCHURCHILL, D. R; SLADE, P. M; YOULE, M et al.Journal of antimicrobial chemotherapy (Print). 2001, Vol 47, Num 3, pp 353-355, issn 0305-7453Article

KNI-272, a highly selective and potent peptidic HIV protease inhibitorDOI, Mitsunobu; ISHIDA, Toshimasa; KATSUYA, Yoshio et al.Acta crystallographica. Section C, Crystal structure communications. 2001, Vol 57, pp 1333-1335, issn 0108-2701, 11Article